Monoclonal Gammopathy of Undetermined Significance in Patients with Psoriasis: Is it Really a Side Effect of Biological Therapy?. (November 2014) - Conti, Andrea
Abstract: Postmarketing Phase IV Moderate‐to‐severe psoriasis is treated using biological drugs targeting cytokines involved in the pathogenesis of the disease, such as tumor necrosis factor alpha (TNF‐α) (adalimumab, infliximab, etanercept) and interleukin 12/23 (IL 12/23) (ustekinumab). There is a slight risk of developing hematological malignancies, such as monoclonal gammopathy of undetermined significance (MGUS) with anti TNF‐α agents. There are no data available on anti‐IL12/23 drugs. This retrospective study of data from 191 patients describes the appearance and follow‐up of MGUS in three patients with psoriasis receiving long‐term biological therapy. Since the appearance of MGUS occurred after about 6 years of anti‐TNFα treatment in only three subjects, it was deemed unlikely to be due to the biological treatment. The decision not to suspend biological therapy after the appearance of MGUS was taken after careful assessment of the possible risks and benefits.